Skip to main content
. Author manuscript; available in PMC: 2013 Jun 1.
Published in final edited form as: Mol Cancer Ther. 2012 Oct 10;11(12):2566–2577. doi: 10.1158/1535-7163.MCT-12-0587

Figure 4. Therapeutic efficacy of RGD4C/Grp78-HSVtk in U87 glioblastoma.

Figure 4

Nude mice bearing U87 xenografts, derived from Luc-expressing U87 cells, were intravenously administered with RGD4C/Grp78-HSVtk, RGD4C/CMV-HSVtk or control vectors. GCV treatment started when tumors reached ~100 mm3 and was given daily until day 17 post-vector delivery then re-administered at day 22. A) Representative images of BLI showing tumor size and tumor viability as visualised by Luc activity at the indicated days post-vector administration. B) Tumor growth curves after GCV treatment. C) Changes in tumor viability before and after GCV treatment as measured by BLI of tumor Luc activity.